International law firm Bird & Bird has advised FIECON on its sale to Herspiegel. The transaction enables Herspiegel, a world leader in pharmaceutical and biotech commercialisation services, to continue its strategic expansion by joining forces with FIECON, Europe’s leading health economics and market access consultancy firm.
This strategic integration expands Herspiegel’s market access capabilities and enhances Herspiegel’s global footprint. The integrated global access services will support patient access to life-saving and life-altering therapies through industry-leading expertise across the access value chain including strategy, health economic modelling, outcomes research, Health Technology Assessments (HTA), value communications, pricing and reimbursement, and Real-World Evidence (RWE).
Herspiegel provides world-class commercialisation services, optimising business outcomes for the world’s largest pharmaceutical and biotech organisations. The addition of FIECON enhances the firm’s European presence with an office in London and deepens its expertise in delivering health economic and market access strategies and evidence to support global reimbursement of medicines and devices.
The Bird & Bird team was led by James Baillieu (partner, Corporate) and included Zoe Bannell-Symes (associate, Corporate), Bryony Warren (associate, Corporate), Max Johnson (associate, Corporate) and Kaya Sapanoglu (trainee solicitor, Corporate), Jesse Dalton (partner, tax), Sarah Ferguson (partner, Tax), Simon Gough (legal director, Tax), David Walder (associate, Tax) and Alexander Beesley (associate, Tax), and Jonathan Goldsworthy (partner, Employment) and Rob Briggs (associate, Employment), among others.
James Baillieu, partner in the Corporate practice at Bird & Bird said: “We were absolutely thrilled to advise FIECON and the sellers on this transaction. FIECON is a leader in the health economics and market access consultancy market and following the transaction we look forward to seeing Herspiegal grow the combined offering in the years ahead. This transaction is yet another example of the excellent corporate work carried out by our leading life sciences practice.”
Kuntal Fisher, CEO of FIECON, commented: “Joining forces with Herspiegel allows us to expand our impact, using economics for the good of humanity with even greater resources and strategic insights. Our shared vision of delivering high-quality, evidence-based solutions makes this partnership a natural fit. We are excited to integrate our expertise in health economics, access strategy, and value communications with Herspiegel’s comprehensive commercialisation services. We were delighted to work with James and the broader Bird & Bird team, whose expertise and experience helped us to successfully complete this transaction. We were impressed with the hard work, dedication and collaborative approach of the entire Bird & Bird team.”
Brent Herspiegel, CEO of Herspiegel commented: “The collaboration with FIECON represents a significant milestone in Herspiegel’s expansion strategy. Bringing together our commercialisation expertise with FIECON’s exceptional capabilities in health economics and HTA strengthens our ability to guide clients through complex regulatory and market access challenges. We are committed to delivering integrated, data-driven solutions that enhance commercial success globally.”
Piper Sandler & Co. served as exclusive financial advisor to FIECON.
